Pancreatic Cancer Research

ResearcherUniversitätsmedizin GöttingenActive in the last 2 years

Bettina Rau Rau

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-8512-622X; OpenAlex author ID A5105250377. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 9

  1. When does delay in treatment impact survival from pancreatic cancer? Co-author DOI 10.1016/j.pan.2025.01.006↗
  2. Patient-derived xenografts from circulating cancer stem cells as a preclinical model for personalized pancreatic cancer research. Co-author DOI 10.1038/s41598-025-87054-z↗
  3. Upregulation of the histone γ-H2AX correlates with worse patient survival and basal-like subtype in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-024-05681-x↗
  4. Cytokeratin 6 identifies basal-like subtypes of pancreatic ductal adenocarcinoma with decreased survival. Co-author DOI 10.1007/s00432-023-04702-5↗
  5. Is treatment in certified cancer centers related to better survival in patients with pancreatic cancer? Evidence from a large German cohort study. Co-author DOI 10.1186/s12885-022-09731-w↗
  6. High compliance with guideline recommendations but low completion rates of adjuvant chemotherapy in resected pancreatic cancer: A cohort study. Last author DOI 10.1016/j.amsu.2018.06.004↗
  7. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Ra… Co-author DOI 10.1200/jco.2017.72.6463↗
  8. Preparing for prospective clinical trials: a national initiative of an excellence registry for consecutive pancreatic cancer resections. Co-author DOI 10.1007/s00268-013-2357-2↗
  9. R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use. Co-author DOI 10.1016/j.surg.2012.05.015↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John Albert Windsor · 1 shared paper, 2025 · strength 0.54
  2. Werner Hartwig · 2 shared papers, 2023–2024 · strength 0.29
  3. Alexander Ioannis Damanakis · 2 shared papers, 2023–2024 · strength 0.29
  4. Felix Popp · 2 shared papers, 2023–2024 · strength 0.29
  5. Alexander Quaas · 2 shared papers, 2023–2024 · strength 0.29
  6. Thomas Schmidt · 2 shared papers, 2023–2024 · strength 0.29
  7. Utz Settmacher · 2 shared papers, 2023–2024 · strength 0.29
  8. Su Ir Lyu · 2 shared papers, 2023–2024 · strength 0.29
  9. Karl Knipper · 2 shared papers, 2023–2024 · strength 0.29
  10. Christiane J. Bruns · 2 shared papers, 2023–2024 · strength 0.29
  11. Yue Zhao · 2 shared papers, 2023–2024 · strength 0.29
  12. Christina Hackl · 1 shared paper, 2025 · strength 0.20
  13. Benedikt J. Wagner · 1 shared paper, 2025 · strength 0.20
  14. Silke Haerteis · 1 shared paper, 2025 · strength 0.20
  15. Veronika Bierbaum · 1 shared paper, 2022 · strength 0.14
  16. Martin Roessler · 1 shared paper, 2022 · strength 0.14
  17. Jochen M. Schmitt · 1 shared paper, 2022 · strength 0.14
  18. Christoph Reißfelder · 1 shared paper, 2022 · strength 0.14
  19. Marius Distler · 1 shared paper, 2022 · strength 0.14
  20. Ernst Klar · 2 shared papers, 2012–2018 · strength 0.13
  21. Malte Weinrich · 1 shared paper, 2018 · strength 0.09
  22. Marcus Bahra · 1 shared paper, 2017 · strength 0.05
  23. Jens Stieler · 1 shared paper, 2017 · strength 0.05
  24. Michael B. Ghadimi · 1 shared paper, 2017 · strength 0.05
  25. Jana Käthe Striefler · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.